Skip to main content
PMC home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2004 Jan;19(1):62–66. doi: 10.1007/BF02872392

Early detection of prostate cancer: evaluating the diagnostic performance of prostate specific antigen by comparing with histological technique among africans

M A Emokpae 1,✉, S C Das 1,✉, T Orok 1, A Z Mohammed 2, S A Hassan 3
PMCID: PMC3453910  PMID: 23105429

Abstract

This study was conducted to investigate the diagnostic performance characteristics of prostate specific antigen (PSA) by comparing serum PSA value with histological findings in patients suspevted of having prostate cancer in Aminu Kano Teaching Hospital. Nigeria. Clinical and Laboratory records were examined and collated for serum PSA values, together with histological findings of biopsy specimen, clinical diagnosis, age of patients, and mode of presentation. The serum PSA values were determined by ELECSYS 1010 autoanalysers Roche, Germany based on electrochemiluminescence immunoassay technique. The results show that serum PSA values increase with age in the assymptomatic non-cancer patients who came for medical check up but were within normal limit. In prostatic disease conditions PSA values were raised in benign prostatic hyperplasia 35.957± 4.0315ng/ml, in undifferentiated carcinoma 56.22±4.295ng/ml and adenocarcinoma >100ng/ml as compared to the normal range (0–4ng/ml). These cases were confirmed by histological diagnosis. It is concluded that PSA evaluations is a sensitive marker for prostate cancer but because of various other conditions that affect serum PSA concentration, other methods of investigations such as Digital Rectal examination, Trans Urethral Ultra-Sonography and histological examination should be combined to confirm diagnosis. Prognosis of patients will be better if early diagnosis is made.

Key words: Prostate specific antigen, Africans

Full Text

The Full Text of this article is available as a PDF (326.2 KB).

References

  • 1.Sagalowsky, A. I. and Wilson, J. D. Hyperplasisa and canciroma of the prostate in Harrison’s principles of internal medicine eds fanci AS. Brannwald, E. J. K., Isselbacher, J. D. Wilsonet al, McGraw-Hill. Health professions division 14th Edition 1998, 596–602.
  • 2.Hass, G. P. and Sakr, W. A. (1997) Epidemiology of prostate cancer. Cancer. J. Clin. 273–277. [DOI] [PubMed]
  • 3.Boring C. C., Squires T. S., Tong T. Cancer statistics. Cancer J. Clin. 1993;43:7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  • 4.Ihde, C. N. and Longe, D. L. Manifestations of cancer in Harrison’s principles of internal medicine Eds. Fanci, A. S., Brauwald, Etu Isselbacher, J. D., Wilson et al McGraw-Hill Health Professions division 14th edition 1998, 360–364.
  • 5.Dawan D., Rafindadi A. H., Kalayi G. D. Benign prostatic hyperplasia and prostatic carcinoma in native Africans. BJU internationnal. 2000;85:1074–1077. doi: 10.1046/j.1464-410x.2000.00677.x. [DOI] [PubMed] [Google Scholar]
  • 6.Alan P. D., Timothy J. C. Diagnosis and Treatment of Urological malignancy: The prostate. Brit. J. Hosp. Med. 1996;3:104–124. [PubMed] [Google Scholar]
  • 7.Oesterling J. E., Jacobson S. T., Chute C. G., et al. Serum prostate-sepecific antigen in a community-Based population of healthy men: Establishment of Age-specific Reference Ranges. JAMA. 1993;270:860–864. doi: 10.1001/jama.270.7.860. [DOI] [PubMed] [Google Scholar]
  • 8.Oesterling J. E. Prostate-specific antigen: a critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. J. Urol. 1991;145:907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  • 9.Robles J. M., Morell A. R., Redorta J. P., Torres, Matoes J.A., Rosello A.S. clinical behaviour of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur. Urol. 1988;14:360–366. doi: 10.1159/000472983. [DOI] [PubMed] [Google Scholar]
  • 10.Christenson A., Bjork T., Nilsson O., et al. Serum prostatic specific antigen completed to alpha 1-antichymotrypsim as an indicator of prostate cancer. J. Urol. 1993;150:100–105. doi: 10.1016/s0022-5347(17)35408-3. [DOI] [PubMed] [Google Scholar]
  • 11.Oesterling J. E., Bilhartz D. C., Tindall D. J. Clinically useful serum markers for adenocarcinoma of the prostate, II: prostate-specific antigen. Am. Urol. Assoc. Update Ser. 1991;10:137–144. [Google Scholar]
  • 12.Information on prostate cancer. Radiotherapy clinic of Georgia (2002) A Centre of Excellence for Prostate Cancer Researches and Treatment http: www.rcog.net/pages/ info.html.
  • 13.Patin A. W., Pound C. R., Clemans J Q., Epstein II, Walsh P. C. Serum PSA after anatomical radical prostectomy. The Hopkins experience after 10 years. Urol. Clin. North Am. 1993;20:713–725. [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES